StephenLouisWeinribMD

PubMed

• 3 citations
  Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.
  Wendy Lane, Stephen L. Weinrib, Michael J. Lawrence, Benjamin C. Lane, Ryan T. Jarrett> ;Endocrine Practice. 2021 Nov 8
• The Effect of Addition of Liraglutide to High Dose Intensive Insulin Therapy:
  Lane, W.,Weinrib, S.,Rappaport, J.,Hale, C.> ;Diabetes Obes Metab. 2014 Mar 05
• 18 citations
  The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients wit...
  Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport, Christopher B. Hale, Lynley K. Farmer, Rebecca S. Lane> ;Endocrine Practice. 2013 Mar 1
• Successful management of differentiated thyroid cancer in a community-based endocrine practice
  Stephen L. Weinrib, Wendy Lane, Jonathan M. Rappaport> ;Endocrine Practice. 2012 Mar 1
• 48 citations
  The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
  Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport> ;Diabetes Technology & Therapeutics. 2011 Apr 27
• 32 citations
  A PROSPECTIVE TRIAL OF U500 INSULIN DELIVERED BY OMNIPOD IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SEVERE INSULIN RESISTANCE
  Wendy Lane, Stephen L. Weinrib, Jonathan M. Rappaport, Therese Przestrzelski> ;Endocrine Practice. 2010 Sep 1
• Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis).
  Tritos, N. A., Weinrib, S., Kaye, T. B.> ;J Intern Med. 1998 Dec
• Join now to see all

Lectures

• Liraglutide Added to High-Dose Basal/Bolus Insulin in Type 2 Diabetes 
  Asheville, NC - 6/15/2014